Mauro Viganò, Alessandro Loglio, Sara Labanca, Serena Zaltron, Francesco Castelli, Pietro Andreone, Vincenzo Messina, Roberto Ganga, Nicola Coppola, Aldo Marrone, Maurizio Russello, Alfredo Marzano, Alessandra Tucci, Gloria Taliani, Massimo Fasano, Stefano Fagiuoli, Erica Villa, Fabrizio Bronte, Teresa Santantonio, Giuseppina Brancaccio, Vincenzo Occhipinti, Floriana Facchetti, Glenda Grossi, Mariagrazia Rumi, Pietro Lampertico
BACKGROUND AND AIMS: Tenofovir disoproxil fumarate (TDF) is recommended for chronic hepatitis B (CHB) treatment, but it may induce kidney dysfunction whose management is not yet known. This Italian, multicentre, retrospective study aimed to assess the efficacy and safety of switching to entecavir (ETV) patients who developed TDF-associated glomerular and/or tubular dysfunction. METHODS: A total of 103 TDF-treated patients were included as follows: age 64 years, 83% male, 49% cirrhotics, 98% with undetectable HBV DNA, 47% with previous lamivudine resistance (LMV-R) and 71% previously treated with adefovir...
March 2019: Liver International: Official Journal of the International Association for the Study of the Liver